PRTA Quote, Financials, Valuation and Earnings

Cosmo Pharmaceuticals NV has a net margin of -102804.76% compared to Prothena Corp. Plc's net margin of --. Prothena Corp. Plc's return on equity of -66.9% beat Cosmo Pharmaceuticals NV's return on equity of 15.06%.

Prothena Corp. Plc has a consensus price target of $20.50, signalling upside risk potential of 127.27%. On the other hand Cosmo Pharmaceuticals NV has an analysts' consensus of -- which suggests that it could fall by --. Given that Prothena Corp. Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Prothena Corp. Plc is more attractive than Cosmo Pharmaceuticals NV.

Prothena Corp. Plc has a beta of -0.113, which suggesting that the stock is 111.323% less volatile than S&P 500. In comparison Cosmo Pharmaceuticals NV has a beta of 0.402, suggesting its less volatile than the S&P 500 by 59.833%.

Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cosmo Pharmaceuticals NV offers a yield of 2.85% to investors and pays a quarterly dividend of $2.34 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Cosmo Pharmaceuticals NV pays out 24.72% of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Prothena Corp. Plc quarterly revenues are $21K, which are larger than Cosmo Pharmaceuticals NV quarterly revenues of --. Prothena Corp. Plc's net income of -$21.6M is higher than Cosmo Pharmaceuticals NV's net income of --. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Cosmo Pharmaceuticals NV's PE ratio is 38.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 50.14x versus 13.09x for Cosmo Pharmaceuticals NV. Usually stocks with elevated PS ratios are considered overvalued.

GH Research Plc has a net margin of -102804.76% compared to Prothena Corp. Plc's net margin of --. Prothena Corp. Plc's return on equity of -66.9% beat GH Research Plc's return on equity of -16.86%.

Prothena Corp. Plc has a consensus price target of $20.50, signalling upside risk potential of 127.27%. On the other hand GH Research Plc has an analysts' consensus of $33.48 which suggests that it could grow by 114.71%. Given that Prothena Corp. Plc has higher upside potential than GH Research Plc, analysts believe Prothena Corp. Plc is more attractive than GH Research Plc.

Prothena Corp. Plc has a beta of -0.113, which suggesting that the stock is 111.323% less volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend.

Prothena Corp. Plc quarterly revenues are $21K, which are larger than GH Research Plc quarterly revenues of --. Prothena Corp. Plc's net income of -$21.6M is lower than GH Research Plc's net income of -$14M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 50.14x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.

Iterum Therapeutics Plc has a net margin of -102804.76% compared to Prothena Corp. Plc's net margin of -2302.31%. Prothena Corp. Plc's return on equity of -66.9% beat Iterum Therapeutics Plc's return on equity of --.

Prothena Corp. Plc has a consensus price target of $20.50, signalling upside risk potential of 127.27%. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 2494.34%. Given that Iterum Therapeutics Plc has higher upside potential than Prothena Corp. Plc, analysts believe Iterum Therapeutics Plc is more attractive than Prothena Corp. Plc.

Prothena Corp. Plc has a beta of -0.113, which suggesting that the stock is 111.323% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.969, suggesting its more volatile than the S&P 500 by 196.931%.

Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend.

Prothena Corp. Plc quarterly revenues are $21K, which are smaller than Iterum Therapeutics Plc quarterly revenues of $390K. Prothena Corp. Plc's net income of -$21.6M is lower than Iterum Therapeutics Plc's net income of -$9M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 50.14x versus 19.91x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -102804.76% compared to Prothena Corp. Plc's net margin of 22.33%. Prothena Corp. Plc's return on equity of -66.9% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Prothena Corp. Plc has a consensus price target of $20.50, signalling upside risk potential of 127.27%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $219.40 which suggests that it could grow by 27.42%. Given that Prothena Corp. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Prothena Corp. Plc is more attractive than Jazz Pharmaceuticals Plc.

Prothena Corp. Plc has a beta of -0.113, which suggesting that the stock is 111.323% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.

Prothena Corp. Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Prothena Corp. Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Prothena Corp. Plc quarterly revenues are $21K, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Prothena Corp. Plc's net income of -$21.6M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Prothena Corp. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Prothena Corp. Plc is 50.14x versus 2.53x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.